{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Drug Updates and Approvals: 2018 in Review
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
The purpose of this learning activity is to provide information about six drugs that received FDA approval in 2018.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the indications, mechanisms of action, and dosages for six drugs that were approved by the FDA in 2018.
- Recognize the adverse reactions, contraindications, warnings, and important nursing implications for these new drugs.
Disclosures
The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
Price:
$17.95
Credits:
- ANCC 1.5 CH / 1.5 APH
- DC - BON 1.5 CH
- KY-BON 1.5 CH
- GA - BON 1.5 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
Awarded Advanced Pharmacology Hours
Awarded Advanced Pharmacology Hours
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: NP1218A
Published: Dec 2018
Expires: 12/31/2026
Required Passing Score: 13/18 (72%)
Topics:
Cystic Fibrosis
,
Drug Update
,
HIV/AIDS
,
Migraine
,
Nausea and Vomiting
,
Opioids
,
Plaque Psoriasis